Biogen Share Price

Biogen Share Price

NASDAQ: BIIB | Large Cap | Healthcare
$249.73
+$2.35 (0.95%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • Similar Stocks
  • FAQs

Biogen Stock Performance

Open
$248.04
Prev. Close
$247.38
Circuit Range
N/A
Day Range
$248.04 - $252.64
Year Range
$161.00 - $260.89
Volume
46,751
Average Traded
$250.01

Biogen Share Price Today

As of 21 November 2026, Biogen Inc.'s share price is $249.73. The stock opened at $248.04, compared to its previous close of $247.38. During today's trading session, Biogen Inc.'s share price traded between $248.04 and $252.64, with an average price of $250.34. Over the past 52 weeks, the stock has recorded a high of $260.89 and a low of $161.00. In terms of performance, Biogen Inc.'s share price has risen by 27.33% over the last six months and is up 37.17% on a year-on-year basis.

Biogen Share Price Chart

Line chart of the Biogen price trend over the selected period. The price rose overall, ranging from 248.04 to 252.64, ending at 249.73.
$248.04$252.64
L
Show Current Price
H

Biogen Stock Fundamentals & Key Indicators

Market Cap
$36.59B
PE Ratio (TTM)
105.12
Dividend Yield
0.00%
EPS (TTM)
$2.35
Revenue (TTM)
$9.89B
Return On Equity (TTM)
1.84%
Profit Margin
13.04%
Debt to Equity
0.41
Quarterly Earnings Growth YoY
57.87%

Biogen Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$2279.40$2477.80$2736.00$2804.10
Net Profit-$48.90$319.50$97.50-$20.60
Net Profit Margin-2.15%12.89%3.56%-0.73%
Income ChangeN/A753.37%-69.48%-121.13%

Biogen Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$10.17$9.84$9.68$9.89
Net Profit$3.05$1.16$1.63$1.29
Net Profit Margin29.99%11.79%16.84%13.04%
Income ChangeN/A-61.97%40.52%-20.86%

Biogen Balance Sheet

All figures in USD Billion

Particulars2025202420232022
Non Current Assets20.4720.5919.9914.76
Current Assets8.977.466.869.79
Total Assets29.4428.0526.8424.55
Non Current Liabilities7.835.88.617.89
Current Liabilities3.355.533.433.27
Total Liabilities11.1811.3312.0511.17
Shareholders' Equity18.2616.7214.813.39

Biogen Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating2,204.62,875.51,547.21,384.3
Investing-1,371.1-799.2-4,101.01,576.6
Financing-301.9-683.5149.3-1,747.3

About Biogen

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Biogen Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$253.61
$249.56
-1.61%
Oct 2026
$224.96
$253.66
+12.17%
Sep 2026
$218.11
$226.14
+2.10%
Aug 2026
$202.63
$221.49
+9.17%
Jul 2026
$215.13
$202.89
-6.07%
Jun 2026
$192.64
$216.00
+10.13%
May 2026
$187.60
$196.13
+3.55%
Apr 2026
$183.49
$189.40
+3.29%
Mar 2026
$190.23
$183.37
-4.34%
Feb 2026
$179.69
$191.69
+6.54%
Jan 2026
$174.93
$179.91
+2.28%
Dec 2025
$181.06
$175.90
-3.38%

Biogen Share Price FAQs